This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joshua, A. M. Articles by Knox, J. J. Search for Related Content PubMed PubMed Citation Articles by Joshua, A. M. Articles by Knox, J. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Adrenal Gland Cancer Cancer Chemotherapy Pheochromocytoma Hazardous Substances DB PYRROLE Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma

Department of Medical Oncology (A.M.J., S.E., R.B., J.J.K.), Princess Margaret Hospital, University Health Network, M5G 2M9 Toronto, Ontario, Canada; and Departments of Pathology (S.L.A., A.E.) and Radiology (M.F.), University Health Network, M5G 2C4, Toronto, Ontario, Canada

Address all correspondence and requests for reprints to: Dr. Jennifer Knox, Department of Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, M5G 2M9 Toronto, Ontario, Canada. E-mail: Jennifer.knox{at}uhn.on.ca.

Context: Paragangliomas are tumors that develop from extraadrenal chromaffin cells. Approximately 20% of paragangliomas are malignant, and surgical resection is considered the primary treatment when possible. The optimal systemic treatment for advanced disease is undefined, due in part to lack of effective agents. Here we report our experience suggesting that sunitinib is an effective agent in this malignancy.

Setting and Patients: Three patients with metastatic paraganglioma were treated with sunitinib at the Princess Margaret Hospital. Limited analyses of tumor tissue and germline DNA were available.

Intervention: Sunitinib at a standard dose (50 mg daily, 4 wk on, 2 wk off) was titrated to patient tolerance.

Results: One patient has achieved a near complete response, and two patients demonstrated partial responses. Two patients demonstrated germline defects suggesting a pseudo-hypoxic drive to the tumor whereas the third demonstrated immunohistochemical evidence of this phenomenon.

Conclusions: Sunitinib appears to be an active agent in this malignancy based on this limited cohort, with an understandable mechanism of action similar to that described in other hypoxia-driven tumors. A single arm phase 2 trial is underway.

This article has been cited by other articles:

				J.-P. Grunfeld Lessons from Rare Renal and Adrenal Diseases Clin. J. Am. Soc. Nephrol., May 1, 2009; 4(5): 870 - 872. [Full Text] [PDF]